Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Sristi Jayaswal

Amgen Stock: Analyst Estimates & Ratings

Amgen Inc. (AMGN) is a leading biopharmaceutical company headquartered in California. The company harnesses advanced biology and technology to discover, develop, manufacture, and deliver innovative medicines for serious illnesses, including cancer, heart disease, osteoporosis, inflammation, and rare diseases. The company’s market capitalization stands at $157.2 billion.

Shares of Amgen have underperformed the broader market over the past 52 weeks. AMGN has declined 7.5% over this time frame, while the broader S&P 500 Index ($SPX) has gained 17.4%. Yet 2025 has been kind, with AMGN rising 12% on a year-to-date (YTD) basis, but still trailing SPX’s 16% YTD gains.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.